Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
670 participants
OBSERVATIONAL
2021-05-11
2027-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This would allow to initiate, following this study, research and development programs on the use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biotherapy Treatment on Features of Microcrystalline Polyarthritis
NCT04005625
Adult Autoimmune Myopathies (MAIA)
NCT04792931
Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
NCT01813617
Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders
NCT05136976
Markers of Favorable Response to FcRn Inhibitors(INFORM)
NCT06685055
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Myasthénie
Blood samples will be collected
No interventions assigned to this group
Myopathie inflammatoire (Myosite)
Blood samples will be collected
No interventions assigned to this group
Neuropathie autoimmune
Blood samples will be collected
No interventions assigned to this group
Néphropathies autoimmunes
Blood samples will be collected
No interventions assigned to this group
Hépatite auto-immune
Blood samples will be collected
No interventions assigned to this group
Pancréatite auto-immune
Blood samples will be collected
No interventions assigned to this group
Purpura Thrombopénique Immunologique
Blood samples will be collected
No interventions assigned to this group
Dermatose bulleuse
Blood samples will be collected
No interventions assigned to this group
Thyroïdite autoimmune
Blood samples will be collected
No interventions assigned to this group
Sclérose en plaque
Blood samples will be collected
No interventions assigned to this group
Sclérose latérale amyotrophique
Blood samples will be collected
No interventions assigned to this group
Polyarthrite Rhumatoïde
Blood samples will be collected
No interventions assigned to this group
Spondylarthrite axiale
Blood samples will be collected
No interventions assigned to this group
controls
Patients without autoimune desease\* Blood samples will be collected
No interventions assigned to this group
Lichen plan buccal auto-immun (LPB)
Blood samples will be collected
No interventions assigned to this group
lichen plan buccal allo-immun liée à une GvHD (" Graft versus Host Disease ")
Blood samples will be collected
No interventions assigned to this group
Lupus érythémateux systémique
Blood samples will be collected
No interventions assigned to this group
Sclérodermie
Blood samples will be collected
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU de Brest - Service de rhumatologie
Brest, Brest, France
Centre Hospitalier des Pays de Morlaix
Morlaix, Brittany Region, France
Centre Hospitalier de Quimper
Quimper, Brittany Region, France
CHU de Martinique
Fort-de-France, Martinique, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Catherine Le Henaff
Role: primary
Jeremy Keraen
Role: primary
Benoit Suzon
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STIMEX - 29BRC21.0025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.